|
Report No. : |
281345.2 |
|
Report Date : |
20.04.2015 |
IDENTIFICATION DETAILS
|
Name : |
MERCKLE GMBH |
|
|
|
|
Registered Office : |
Ludwig-Merckle-Str. 3, D 89143
Blaubeuren |
|
|
|
|
Country : |
Germany |
|
|
|
|
Financials (as on) : |
31.12.2012 |
|
|
|
|
Date of Incorporation : |
2004 |
|
|
|
|
Legal Form : |
Private Limited Company |
|
|
|
|
Line of Business : |
·
Manufacture of other chemical products ·
Manufacture of pharmaceutical
preparations |
|
|
|
|
No. of Employees : |
1,865 |
RATING & COMMENTS
|
MIRA’s Rating : |
Ba |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
Status : |
Satisfactory |
|
Payment Behaviour : |
No Complaints |
|
Litigation : |
Clear |
NOTES:
Any query related to this report can be made
on e-mail: infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – December 31, 2014
|
Country Name |
Previous Rating (30.09.2014) |
Current Rating (31.12.2014) |
|
Germany |
A1 |
A1 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
GERMANY - ECONOMIC OVERVIEW
The German economy - the fifth largest economy in the world
in PPP terms and Europe's largest - is a leading exporter of machinery, vehicles,
chemicals, and household equipment and benefits from a highly skilled labor
force. Like its Western European neighbors, Germany faces significant
demographic challenges to sustained long-term growth. Low fertility rates and
declining net immigration are increasing pressure on the country's social
welfare system and necessitate structural reforms. Reforms launched by the
government of Chancellor Gerhard SCHROEDER (1998-2005), deemed necessary to
address chronically high unemployment and low average growth, contributed to
strong growth and falling unemployment. These advances, as well as a government
subsidized, reduced working hour scheme, help explain the relatively modest
increase in unemployment during the 2008-09 recession - the deepest since World
War II - and its decrease to 5.3% in 2014. The new German government introduced
a minimum wage of about $11.60 (8.50 euros) per hour to take effect in 2015.
Stimulus and stabilization efforts initiated in 2008 and 2009 and tax cuts
introduced in Chancellor Angela MERKEL's second term increased Germany's total
budget deficit - including federal, state, and municipal - to 4.1% in 2010, but
slower spending and higher tax revenues reduced the deficit to 0.8% in 2011 and
in 2012 Germany reached a budget surplus of 0.1%. The budget was essentially in
balance in 2014. A constitutional amendment approved in 2009 limits the federal
government to structural deficits of no more than 0.35% of GDP per annum as of
2016 though the target was already reached in 2012. Following the March 2011
Fukushima nuclear disaster, Chancellor Angela MERKEL announced in May 2011 that
eight of the country's 17 nuclear reactors would be shut down immediately and
the remaining plants would close by 2022. Germany plans to replace nuclear power
with renewable energy, which accounts for 34% of total energy consumption, up
from 9% in 2000. Before the shutdown of the eight reactors, Germany relied on
nuclear power for 23% of its electricity generating capacity and 46% of its
base-load electricity production.
|
Source
: CIA |
MERCKLE GMBH
Company Status: active
Ludwig-Merckle-Str. 3
D 89143 Blaubeuren
Telephone:07344/140
Telefax: 07344/141620
Homepage: www.teva.de
E-mail:
info.teva-deutschland@teva.de
VAT
no.: DE239707564
Business relations are permissible.
LEGAL FORM Private limited company
Date of foundation: 2004
Shareholders'
agreement: 14.12.2004
Registered on: 22.02.2005
Commercial Register: Local court 89073 Ulm
under: HRB 5125
Share capital: EUR 500,000.00
Shareholder:
TEVA Health GmbH
Graf-Arco-Str. 3
D 89079 Ulm
Legal form: Private
limited company
Share capital: EUR 25,000.00
Share: EUR 500,000.00
Registered on: 22.12.2010
Reg. data: 89073 Ulm, HRB
725926
Manager:
Dr. Markus Guilherme
Leyck Dieken
D 10115 Berlin
born: 22.11.1964
Manager:
Dr. Gerald Huber
D 73655 Plüderhausen
born: 25.05.1966
Manager:
Andreas Martin Burkhardt
D 89231 Neu-Ulm
born: 07.04.1976
Manager:
Tihomir Oreskovic
NL Amsterdam
born: 01.01.1966
Nationality: Dutch
Manager:
Dr. Miran Denac
CH Brunnen
born: 04.04.1957
Proxy:
Nicole von Gregory
D 01445 Radebeul
authorized to jointly
represent the company
born: 19.07.1969
Proxy:
Stefan Winghardt
D 88471 Laupheim
authorized to jointly
represent the company
born: 08.07.1969
Further
functions/participations of Dr. Markus Guilherme Leyck
Dieken (Manager)
Manager:
ratiopharm GmbH
Graf-Arco-Str. 3
D 89079 Ulm
Legal form: Private
limited company
Share capital: EUR 414,000.00
Registered
on: 29.10.1979
Reg. data: 89073 Ulm, HRB 991
Manager:
TEVA GmbH
Graf-Arco-Str. 3
D 89079 Ulm
Legal form: Private
limited company
Share capital: EUR 894,760.79
Registered
on: 18.08.2011
Reg. data: 89073 Ulm, HRB 726876
Manager:
AbZ-Pharma GmbH
Graf-Arco-Str. 3
D 89079 Ulm
Legal form: Private
limited company
Share capital: EUR 26,000.00
Registered
on: 08.06.1998
Reg. data: 89073 Ulm, HRB 3643
Manager:
TEVA Pharma GmbH
Graf-Arco-Str. 3
D 89079 Ulm
Legal form: Private
limited company
Share capital: EUR 1,022,583.76
Registered
on: 21.07.2011
Reg. data: 89073 Ulm, HRB 726775
Manager:
Merckle Biotec GmbH
Dornierstr. 10
D 89079 Ulm
Legal form: Private
limited company
Share capital: EUR 25,000.00
Registered
on: 10.08.2004
Reg. data: 89073 Ulm, HRB 4990
Manager:
Transpharm Logistik GmbH
Nicolaus-Otto-Str. 16
D 89079 Ulm
Legal form: Private
limited company
Share capital: EUR 50,000.00
Registered
on: 12.02.1986
Reg. data: 89073 Ulm, HRB 1714
Manager:
TEVA Health GmbH
Graf-Arco-Str. 3
D 89079 Ulm
Legal form: Private
limited company
Share capital: EUR 25,000.00
Registered
on: 22.12.2010
Reg. data: 89073 Ulm, HRB 725926
Manager:
Pliva Real Estate GmbH
Charlottenstr. 59
D 10117 Berlin
Legal form: Private
limited company
Share capital: EUR 25,000.00
Registered
on: 27.12.2011
Reg. data: 14057 Berlin, HRB 138844 B
Vice-president of the Board of Directors:
Pro Generika e.V.
Unter den Linden 32-34
D 10117 Berlin
Legal form: Registered association
Registered
on: 11.07.2006
Reg. data: 14057 Berlin, VR 23462
Further functions/participations of Dr. Gerald
Huber (Manager)
Manager:
ratiopharm GmbH
Graf-Arco-Str. 3
D 89079 Ulm
Legal form: Private
limited company
Share capital: EUR 414,000.00
Registered
on: 29.10.1979
Reg. data: 89073 Ulm, HRB 991
Further functions/participations of Andreas
Martin Burkhardt
(Manager)
Manager:
AbZ-Pharma GmbH
Graf-Arco-Str. 3
D 89079 Ulm
Legal form: Private
limited company
Share capital: EUR 26,000.00
Registered
on: 08.06.1998
Reg. data: 89073 Ulm, HRB 3643
Manager:
TEVA Pharma GmbH
Graf-Arco-Str. 3
D 89079 Ulm
Legal form: Private
limited company
Share capital: EUR 1,022,583.76
Registered
on: 21.07.2011
Reg. data: 89073 Ulm, HRB 726775
Manager:
TEVA GmbH
Graf-Arco-Str. 3
D 89079 Ulm
Legal form: Private
limited company
Share capital: EUR 894,760.79
Registered
on: 18.08.2011
Reg. data: 89073 Ulm, HRB 726876
Manager:
Merckle Biotec GmbH
Dornierstr. 10
D 89079 Ulm
Legal form: Private
limited company
Share capital: EUR 25,000.00
Registered
on: 10.08.2004
Reg. data: 89073 Ulm, HRB 4990
Manager:
Transpharm Logistik GmbH
Nicolaus-Otto-Str. 16
D 89079 Ulm
Legal form: Private
limited company
Share capital: EUR 50,000.00
Registered
on: 12.02.1986
Reg. data: 89073 Ulm, HRB 1714
Manager:
ratiopharm GmbH
Graf-Arco-Str. 3
D 89079 Ulm
Legal form: Private
limited company
Share capital: EUR 414,000.00
Registered
on: 29.10.1979
Reg. data: 89073 Ulm, HRB 991
Manager:
TEVA Health GmbH
Graf-Arco-Str. 3
D 89079 Ulm
Legal form: Private
limited company
Share capital: EUR 25,000.00
Registered
on: 22.12.2010
Reg. data:
89073 Ulm, HRB 725926
Proxy:
Pliva Real Estate GmbH
Charlottenstr. 59
D 10117 Berlin
Legal form: Private
limited company
Share capital: EUR 25,000.00
Registered
on: 27.12.2011
Reg. data: 14057 Berlin, HRB 138844 B
Further functions/participations of Tihomir
Oreskovic (Manager)
Manager:
TEVA Pharma GmbH
Graf-Arco-Str. 3
D 89079 Ulm
Legal form: Private
limited company
Share capital: EUR 1,022,583.76
Registered
on: 21.07.2011
Reg. data: 89073 Ulm, HRB 726775
Manager:
TEVA GmbH
Graf-Arco-Str. 3
D 89079 Ulm
Legal form: Private
limited company
Share capital: EUR 894,760.79
Registered
on: 18.08.2011
Reg. data: 89073 Ulm, HRB 726876
Manager:
Transpharm Logistik GmbH
Nicolaus-Otto-Str. 16
D 89079 Ulm
Legal form: Private
limited company
Share capital: EUR 50,000.00
Registered
on: 12.02.1986
Reg. data: 89073 Ulm, HRB 1714
Manager:
ratiopharm GmbH
Graf-Arco-Str. 3
D 89079 Ulm
Legal form: Private
limited company
Share capital: EUR 414,000.00
Registered
on: 29.10.1979
Reg. data: 89073 Ulm, HRB 991
Manager:
TEVA Health GmbH
Graf-Arco-Str. 3
D 89079 Ulm
Legal form: Private
limited company
Share capital: EUR 25,000.00
Registered
on: 22.12.2010
Reg. data: 89073 Ulm, HRB 725926
Manager:
Merckle Biotec GmbH
Dornierstr. 10
D 89079 Ulm
Legal form: Private
limited company
Share capital: EUR 25,000.00
Registered
on: 10.08.2004
Reg. data: 89073 Ulm, HRB 4990
Further
functions/participations of Dr. Miran Denac (Manager)
Manager:
TEVA GmbH
Graf-Arco-Str. 3
D 89079 Ulm
Legal form: Private
limited company
Share capital: EUR 894,760.79
Registered
on: 18.08.2011
Reg. data: 89073 Ulm, HRB 726876
Manager:
Transpharm Logistik GmbH
Nicolaus-Otto-Str. 16
D 89079 Ulm
Legal form: Private
limited company
Share capital: EUR 50,000.00
Registered
on: 12.02.1986
Reg. data: 89073 Ulm, HRB 1714
Manager:
ratiopharm GmbH
Graf-Arco-Str. 3
D 89079 Ulm
Legal form: Private
limited company
Share capital: EUR 414,000.00
Registered
on: 29.10.1979
Reg. data: 89073 Ulm, HRB 991
27.12.2004 - 22.02.2005 VEM Produktion GmbH (HRB 23252 AG
Dresden)
Wilhelm-Liebknecht-Str. 6
D 01257 Dresden
Private limited
company
22.02.2005 - 02.11.2012 Merckle GmbH
Ludwig-Merckle-Str. 3
D 89143 Blaubeuren
Private limited
company
02.11.2012 - 26.11.2012 Merckle GmbH
Graf-Arco-Str. 3
D 89079 Ulm
Private limited
company
Main industrial sector
2059
Manufacture of other chemical products n.e.c.
2120
Manufacture of pharmaceutical preparations
Secondary industrial sector
7219
Other research and experimental development on natural
sciences and engineering
Average risk of default: 2.3 %
Branch:
Merckle GmbH
Graf-Arco-Str. 3 OT
Donautal
D 89079 Ulm
TEL.: 0731/40201
FAX.: 0731/4027832
General partner:
Gen-Plus GmbH & Co KG
Staffelseestr. 6
D 81477 München
Legal form: Ltd
partnership with priv. ltd.
company as
general partner
Company Status: active
Total cap. EUR 500,000.00
contribution:
Reg. data: 06.02.2012
Local court
80333 München
HRA 98523
Shareholder:
ratiopharm GmbH
Graf-Arco-Str. 3
D 89079 Ulm
Legal form: Private
limited company
Company Status: active
Share capital: EUR 414,000.00
Share: EUR 414,000.00
Reg. data: 29.10.1979
Local court
89073 Ulm
HRB 991
Shareholder:
Transpharm Logistik GmbH
Nicolaus-Otto-Str. 16
D 89079 Ulm
Legal form: Private
limited company
Company Status: active
Share capital: EUR 50,000.00
Share: EUR 50,000.00
Reg. data: 12.02.1986
Local court
89073 Ulm
HRB 1714
Shareholder:
Asma Investment GmbH
Zehrensdorfer Str. 4
D 15806 Zossen
Legal form: Private
limited company
Company Status: active
Share capital: EUR 25,000.00
Share: EUR 25,000.00
Reg. data: 18.11.2009
Local court
14467 Potsdam
HRB 22682 P
Shareholder:
Merckle Biotec GmbH
Dornierstr. 10
D 89079 Ulm
Legal form: Private
limited company
Company Status: active
Share capital: EUR 25,000.00
Share: EUR 25,000.00
Reg. data: 10.08.2004
Local court
89073 Ulm
HRB 4990
Payment experience: within periods customary in this trade
Negative information: We have no negative
information at hand.
Type of ownership: Tenant
Address Graf-Arco-Str. 3
D 89079 Ulm
Type of ownership: Tenant
Address Ludwig-Merckle-Str. 3
D 89143 Blaubeuren
Land register documents were not available.
Principal bank
DEUTSCHE BANK, 89006 ULM, DONAU
Sort. code: 63070088
BIC: DEUTDESS630
Further bank
COMMERZBANK, 89005 ULM, DONAU
Sort. code: 63040053
BIC: COBADEFFXXX
FINANCIAL
FIGURES
Equipment: EUR 15,181,772.00
Ac/ts receivable: EUR 215,618,290.00
Liabilities: EUR 710,745,172.00
Employees: 1,865
-
thereof permanent staff: 1,865
Balance sheet ratios 01.01.2012 - 31.12.2012
Equity ratio [%]: 90.05
Liquidity ratio: 0.93
Return on total capital [%]: 3.83
Balance sheet ratios 01.01.2011 - 31.12.2011
Equity ratio [%]: 92.55
Liquidity ratio: 2.18
Return on total capital [%]: 7.73
Balance sheet ratios 01.10.2010 - 31.12.2010
Equity
ratio [%]: 85.42
Liquidity ratio: 0.26
Return on total capital [%]: 1.60
EQUITY RATIO
The
equity ratio indicates the portion of the equity as compared
to
the total capital. The higher the equity ratio, the better the
economic stability (solvency) and thus the
financial autonomy of
a
company.
LIQUIDITY RATIO
The
liquidity ratio shows the proportion between adjusted
receivables and net liabilities. The higher
the ratio, the lower
the
company's financial dependancy from external creditors.
RETURN ON TOTAL CAPITAL
The
return on total capital shows the efficiency and return on
the
total capital employed in the company. The higher the return
on
total capital, the more economically does the company work
with the invested capital.
Balance sheet grade
The
balance sheet grade is based on the following ratios: equity
ratio, liquidity ratio and return on total
capital from the
balance sheets published in the Federal
Gazette. It is calculated
in accordance
with the methodology of Euler Hermes. It ranges
from 1.0 (positive) to 5.0 (negative).
Type
of balance sheet: Company balance sheet
Financial year: 01.01.2012 - 31.12.2012
ASSETS EUR 2,731,268,287.92
Fixed assets
EUR 2,125,268,389.41
Intangible assets
EUR 3,335,894.00
Concessions, licences, rights
EUR 3,219,894.00
Advance payments for intang. assets
EUR 116,000.00
Tangible assets
EUR 77,376,228.78
Land / similar rights
EUR 1,748,746.00
Plant / machinery
EUR 41,588,171.00
Other tangible assets / fixtures and
fittings
EUR 15,181,772.08
Advance payments made / construction
in progress
EUR 18,857,539.70
Financial assets
EUR 2,044,556,266.63
Shares in participations /
subsidiaries and the like
EUR 2,044,556,266.63
Shares in related companies
EUR 2,044,556,266.63
Current assets
EUR 604,196,865.28
Stocks EUR 388,185,205.99
Raw materials, consumables and
supplies
EUR 58,880,378.42
Finished goods / work in progress
EUR 329,304,827.57
Accounts receivable
EUR 215,618,289.50
Trade debtors
EUR 41,669,858.18
Amounts due from related companies
EUR 159,122,256.66
Other debtors and assets
EUR 14,826,174.66
Liquid means EUR 393,369.79
Remaining other assets
EUR 1,803,033.23
Accruals (assets)
EUR 1,133,558.51
Active difference from asset
offsetting
EUR 669,474.72
LIABILITIES EUR 2,731,268,287.92
Shareholders' equity
EUR 1,980,911,549.87
Capital
EUR 500,000.00
Subscribed capital (share capital)
EUR 500,000.00
Reserves
EUR 1,975,968,586.92
Capital reserves
EUR 1,975,756,890.07
Retained earnings / revenue reserves EUR 211,696.85
Balance sheet profit/loss (+/-)
EUR 4,442,962.95
Balance sheet profit / loss
EUR 4,442,962.95
Provisions
EUR 39,611,565.96
Pension provisions and comparable
provisions
EUR 4,776,876.00
Provisions for taxes
EUR 596.02
Other / unspecified provisions
EUR 34,834,093.94
Liabilities
EUR 710,745,172.09
Other liabilities EUR 710,745,172.09
Trade creditors (for IAS incl. bills
of exchange)
EUR 72,969,908.62
Liabililties due to related companiesEUR 634,442,231.80
Unspecified other liabilities
EUR 3,333,031.67
thereof liabilities from tax /
financial authorities
EUR 1,783,152.14
Guarantees and other commitments
EUR 5,000,000.00
Guarantees / warranties
EUR 5,000,000.00
Guarantees
EUR 5,000,000.00
PROFIT AND LOSS ACCOUNT (cost-summary method)
according to Comm.
Code
(HGB)
Sales
EUR 986,333,961.82
Inventory change + own costs (+/-)
EUR -3,926,475.67
Inventory change (+/-)
EUR -3,926,475.67
Other operating income
EUR 7,935,490.53
Cost of materials
EUR 759,639,409.14
Raw materials and supplies, purchased
goods
EUR 759,639,409.14
Gross result (+/-)
EUR 230,703,567.54
Staff expenses
EUR 115,174,656.05
Wages and salaries
EUR 96,757,951.08
Social security contributions and
expenses for pension plans and
benefits
EUR 18,416,704.97
Total depreciation
EUR 16,475,051.22
Depreciation on tangible / intangible
asssets (incl. start-up and exp. of
bus.
EUR 16,475,051.22
Other operating expenses
EUR 138,484,464.64
Operating result from continuing
operations EUR -39,430,604.37
Result from participating interests
(+/-)
EUR 161,941,291.84
Expenses / income from participations EUR 169,144,972.69
Income from transfer of profits
EUR 169,144,972.69
Expenses for participations
EUR 7,203,680.85
Expenses for other participations
EUR 7,203,680.85
Interest result (+/-)
EUR -14,203,686.05
Interest and similar income
EUR 537,276.64
thereof from related companies
EUR 1,336.12
Interest and similar expenses
EUR 14,740,962.69
thereof paid to related companies
EUR 14,039,221.62
Other financial result EUR -692,021.16
Depreciation on financial assets and
marketable securities
EUR 692,021.16
Financial result (+/-)
EUR 147,045,584.63
Result from ordinary operations (+/-)
EUR 107,614,980.26
Extraordinary income
EUR 3,282,422.09
Extraordinary expenses
EUR 36,629.01
Extraordinary result (+/-)
EUR 3,245,793.08
Expenses for transfer of profits to a
parent company
EUR 107,903,767.04
Income tax / refund of income tax (+/-)EUR -2,125,784.50
Other taxes / refund of taxes
EUR -831,221.80
Tax
(+/-) EUR -2,957,006.30
Annual surplus / annual deficit
EUR 0.00
Type
of balance
sheet: Company balance sheet
Financial year: 01.01.2011 - 31.12.2011
ASSETS EUR 2,793,330,301.63
Fixed assets
EUR 2,077,064,268.96
Intangible assets
EUR 2,013,745.00
Concessions, licences, rights
EUR 2,013,745.00
Tangible assets
EUR 62,364,862.10
Land / similar rights
EUR 1,816,667.00
Plant / machinery
EUR 30,565,637.00
Other tangible assets / fixtures and
fittings
EUR 15,716,026.00
Advance payments made / construction
in progress
EUR 14,266,532.10
Financial assets
EUR 2,012,685,661.86
Shares in participations /
subsidiaries and the like EUR
2,012,685,661.86
Shares in related companies
EUR 2,012,685,661.86
Current assets
EUR 715,200,732.43
Stocks
EUR 351,819,586.08
Raw materials, consumables and
supplies
EUR 69,680,335.36
Finished goods / work in progress
EUR 280,974,561.72
Advance payments made
EUR 1,164,689.00
Accounts receivable
EUR 361,067,793.07
Trade debtors
EUR 27,524,534.64
Amounts due from related companies
EUR 315,076,091.11
Other debtors and assets
EUR 18,467,167.32
Liquid means EUR 2,313,353.28
Remaining other assets
EUR 1,065,300.24
Accruals (assets)
EUR 895,960.75
Active difference from asset
offsetting
EUR 169,339.49
LIABILITIES EUR 2,793,330,301.63
Shareholders' equity
EUR 1,980,911,549.87
Capital
EUR 500,000.00
Subscribed capital (share capital)
EUR 500,000.00
Reserves
EUR 1,975,968,586.92
Capital reserves
EUR 1,975,756,890.07
Retained earnings / revenue reserves EUR 211,696.85
Balance sheet profit/loss (+/-)
EUR 4,442,962.95
Profit / loss brought forward
EUR 4,442,962.95
Provisions
EUR 40,290,450.85
Pension provisions and comparable
provisions
EUR 4,750,968.00
Provisions for taxes
EUR 419.58
Other / unspecified provisions
EUR 35,539,063.27
Liabilities
EUR 772,128,300.91
Other liabilities EUR
772,128,300.91
Trade creditors (for IAS incl. bills
of exchange)
EUR 96,576,853.05
Liabililties due to related companiesEUR 673,317,449.87
Unspecified other liabilities
EUR 2,233,997.99
thereof liabilities from tax /
financial authorities
EUR 1,882,339.47
PROFIT AND LOSS ACCOUNT (cost-summary method)
according to Comm.
Code
(HGB)
Sales
EUR 858,551,998.01
Inventory change + own costs (+/-)
EUR 1,263,914.54
Inventory change (+/-)
EUR 1,263,914.54
Other operating income
EUR 26,160,157.50
Cost of materials
EUR 629,271,083.07
Raw materials and supplies, purchased
goods
EUR 629,271,083.07
Gross result (+/-)
EUR 256,704,986.98
Staff expenses
EUR 104,570,760.34
Wages and salaries
EUR 87,871,758.07
Social security contributions and
expenses for pension plans and
benefits
EUR 16,699,002.27
Total depreciation
EUR 17,712,086.37
Depreciation on tangible / intangible
asssets (incl. start-up and exp. of
bus.
EUR 17,712,086.37
Other operating expenses
EUR 112,616,170.52
Operating result from continuing
operations
EUR 21,805,969.75
Result from participating interests
(+/-)
EUR 216,434,450.12
Expenses / income from participations EUR 216,434,450.12
Income from transfer of profits
EUR 216,430,061.08
Income from related companies
EUR 4,389.04
Expenses for the transfer of losses
EUR 7,169,484.85
Interest result (+/-)
EUR -14,066,666.76
Interest and similar income
EUR 7,110,785.67
thereof from related companies
EUR 6,974,481.67
Interest and similar expenses
EUR 21,177,452.43
thereof paid to related companies EUR
21,085,002.11
Other financial result
EUR -1,430.64
Depreciation on financial assets and
marketable securities
EUR 1,430.64
Financial result (+/-)
EUR 195,196,867.87
Result from ordinary operations (+/-)
EUR 217,002,837.62
Extraordinary income
EUR 626,312.76
Extraordinary result (+/-)
EUR 626,312.76
Expenses for transfer of profits to a
parent company EUR 216,639,616.15
Income tax / refund of income tax (+/-)EUR -1,092.58
Other taxes / refund of taxes
EUR -988,441.65
Tax
(+/-)
EUR -989,534.23
Annual surplus / annual deficit
EUR 0.00
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.62.35 |
|
|
1 |
Rs.93.10 |
|
Euro |
1 |
Rs.67.13 |
INFORMATION DETAILS
|
Analysis Done by
: |
SUB |
|
|
|
|
Report Prepared
by : |
TPT |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest capability
for timely payment of interest and principal sums |
Unlimited |
|
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
|
41-55 |
Ba |
Overall operation
is considered normal. Capable to meet normal commitments. |
Satisfactory |
|
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
|
-- |
NB |
New Business |
-- |
|
This score serves as a reference to assess
SC’s credit risk and to set the amount of credit to be extended. It is
calculated from a composite of weighted scores obtained from each of the major sections
of this report. The assessed factors and their relative weights (as indicated
through %) are as follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend (10%) Operational size
(10%)
This report is issued at your request without any risk
and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL) or its
officials.